EHA 2022 | Updates from the Phase I/II BRUIN study: pirtobrutinib in CLL
In this video, Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some updates from the Phase I/II BRUIN study (NCT03740529) evaluating the use of pirtobrutinib for the treatment of B-cell malignancies, drawing focus on patients with chronic lymphocytic leukemia (CLL). Dr Eyre first gives some background information on pirtobrutinib and the patient population in this study, and then goes on to discuss some results, including overall response rates (ORR) and progression-free survival (PFS), as well as the importance of this agent for the future treatment of high-risk patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Roche: Education Honorarium, Advisory Board Honorarium, Travel to scientific conferences
Gilead: Honorarium; Research support; Travel to scientific conferences
KITE: Education Honorarium, Advisory Board Honorarium,
Janssen: Honorarium
Abbvie: Honorarium; Travel to scientific conferences
AstraZeneca: Honorarium, Research funding, Travel to scientific conferences
Loxo Oncology: Advisory Board Honorarium, Trial steering committee
Beigene: Advisory Board Honorarium, Research funding
Incyte: Advisory Board Honorarium
Secura Bio: Advisory Board Honorarium
